Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2025 07:01 ET | Source: Pasithea

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea completes enrollment and dosing of first NF1 trial cohort; initial safety and efficacy data expected by Q1 2026.
April 29, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics completes Cohort 6 enrollment and dosing in Phase 1 PAS-004 trial for MAPK-driven advanced cancers; full enrollment by 2025.
December 18, 2024 08:30 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor